Gabapentin (Epilepsy) updated on 04-22-2025

Neuro-developmental disorders (as a whole)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18744
R79705		 Moore (Gabapentin) (Epilepsy) (Controls exposed to LTG), 2025 Early childhood developmental concerns (any developmental concerns on any domain at the 27–30 month assessment offered to all children) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 0.59 [0.13;2.73] C
excluded (control group) 		2/12   90/354 92 12
ref
S18743
R79702		 Moore (Gabapentin) (Epilepsy) (Controls unexposed, sick), 2025 Early childhood developmental concerns (any developmental concerns on any domain at the 27–30 month assessment offered to all children) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No Matched 0.73 [0.15;3.46] 2/12   26/120 28 12
ref
S6252
R16652		 Arkilo (Gabapentin), 2015 Abnormal development (At 2 years of age, assessed by developmental specialists) during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: No 8.60 [0.14;536.34] C 0/1   2/24 2 1
ref
S6682
R18547		 Dean (Gabapentin), 2002 Developmental delay at least 1st trimester retrospective cohort unexposed, sick Adjustment: No 7.44 [0.13;423.73] C 0/1   4/38 4 1
ref
Total 3 studies 1.29 [0.31;5.34] 34 14
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Moore (Gabapentin) (Epilepsy) (Controls unexposed, sick), 2025Moore, 2025 1 0.73[0.15; 3.46]281276%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: low Arkilo (Gabapentin), 2015Arkilo, 2015 2 8.60[0.14; 536.34]2112%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Dean (Gabapentin), 2002Dean, 2002 3 7.44[0.13; 423.73]4112%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 2% 1.29[0.31; 5.34]34140.220.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Gabapentin) (Epilepsy) (Controls unexposed, sick; 2: Gabapentin; 3: Gabapentin;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.29[0.31; 5.34]34142%NAMoore (Gabapentin) (Epilepsy) (Controls unexposed, sick), 2025 Arkilo (Gabapentin), 2015 Dean (Gabapentin), 2002 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.07[0.20; 5.81]32139%NAMoore (Gabapentin) (Epilepsy) (Controls unexposed, sick), 2025 Dean (Gabapentin), 2002 2 exposed to other treatment, sickexposed to other treatment, sick 8.60[0.14; 536.34]21 -NAArkilo (Gabapentin), 2015 1 Tags Adjustment   - No  - No 1.29[0.31; 5.34]34142%NAMoore (Gabapentin) (Epilepsy) (Controls unexposed, sick), 2025 Arkilo (Gabapentin), 2015 Dean (Gabapentin), 2002 3 MatchedMatched 0.73[0.15; 3.51]2812 -NAMoore (Gabapentin) (Epilepsy) (Controls unexposed, sick), 2025 1 All studiesAll studies 1.29[0.31; 5.34]34142%NAMoore (Gabapentin) (Epilepsy) (Controls unexposed, sick), 2025 Arkilo (Gabapentin), 2015 Dean (Gabapentin), 2002 30.220.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 18744

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.07[0.20; 5.81]32139%NAMoore (Gabapentin) (Epilepsy) (Controls unexposed, sick), 2025 Dean (Gabapentin), 2002 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.10[0.12; 10.22]941330%NAMoore (Gabapentin) (Epilepsy) (Controls exposed to LTG), 2025 Arkilo (Gabapentin), 2015 20.510.01.0